Lasa Supergenerics Ltd
Lasa Supergenerics Ltd Live Price Chart
Performance
| Previous Close | ₹ 6.97 |
| High | ₹ 7.42 |
| Volume | 69589 |
| 52W Range | ₹ - ₹ |
| Open | ₹ 7 |
| Low | ₹ 6.85 |
| Market Cap | ₹ 34.17 Cr |
Lasa Supergenerics Ltd Technicals
| 20 Day | ₹ 7.201 |
| 50 Day | ₹ 7.334 |
| 100 Day | ₹ 7.619 |
| 200 Day | ₹ 8.916 |
| 20 Day | ₹ 7.297 |
| 50 Day | ₹ 7.306 |
| 100 Day | ₹ 7.584 |
| 200 Day | ₹ 8.343 |
Lasa Supergenerics Ltd Fundamentals
| ROCE | -22.206 |
| P/E Ratio | -2.100 |
| P/B Ratio | 0.700 |
| Industry P/E | 0.700 |
| Debt to Equity | 51.431 |
| ROE | -26.304 |
| EPS | -3.300 |
| Dividend Yield | 0.000 |
| Book Value | 9.904 |
| Face Value | 10.000 |
Lasa Supergenerics Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 147.4603 | 104.4343 | 131.3724 | 137.4014 | 202.4371 |
| Total Expenses | 151.1743 | 114.7737 | 153.7409 | 135.6803 | 172.9457 |
| Profit After Tax | -14.7573 | -21.7306 | -38.6207 | -5.3313 | 22.7777 |
Lasa Supergenerics Ltd Shareholding Pattern
| Promoter Holdings | 53.651 % |
| FIIs | 0.000 % |
| DIIs | 0.000 % |
| MutualFund | 0.000 % |
| Retail | 42.038 % |
| Others - | 4.312 % |
About Lasa Supergenerics Ltd
Lasa Supergenerics Limited was incorporated on March 11, 2016. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. The Company is a veterinary API manufacturing entity, which was acquired in April, 2012. The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra. It specialises in catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India. To efficiently control the supply chain, the Company is fully backward integrated for its key molecules-from discovery research up to full-scale bulk production. The Company's marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future. The Company launched two new block buster products with all-time strong segment, Oxycozanide. Oxyclozanide is an anthelmintic, used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle, especially buffalos in farm, sheep, and goats. For this, the Compan ...
Similar Stocks
| Ambalal Sarabhai Enterprises Ltd Pharmaceuticals | ₹ 44.01 +0.88 (+2.04%) |
| Amrutanjan Health Care Ltd Pharmaceuticals | ₹ 514.25 -2.8 (-0.54%) |
| Astrazeneca Pharma India Ltd Pharmaceuticals | ₹ 7,106.50 -29.5 (-0.41%) |
| Bliss GVS Pharma Ltd Pharmaceuticals | ₹ 588.10 +28 (+5%) |
| Abbott India Ltd Pharmaceuticals | ₹ 26,175.00 -175 (-0.66%) |
| Cipla Ltd Pharmaceuticals | ₹ 1,423.50 +3.5 (+0.25%) |
FAQs on Lasa Supergenerics Ltd
1. Can I buy Lasa Supergenerics Ltd from PL Capital? ›
2. Does Lasa Supergenerics Ltd pay dividends? ›
3. What is the current share price of Lasa Supergenerics Ltd ? ›
4. What is the 52-week high and low of Lasa Supergenerics Ltd ? ›
Start SIP in Lasa Supergenerics Ltd
Invest systematically in stocks with the
PL Capital app
Are you a new user? Open your account
